These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30419293)

  • 1. Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis.
    Vaddady PK; Trivedi A; Rathi C; Madhura DB; Liu J; Lee RE; Meibohm B
    Eur J Pharm Sci; 2019 Jan; 127():233-239. PubMed ID: 30419293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions.
    Liu J; Bruhn DF; Lee RB; Zheng Z; Janusic T; Scherbakov D; Scherman MS; Boshoff HI; Das S; Rakesh ; Waidyarachchi SL; Brewer TA; Gracia B; Yang L; Bollinger J; Robertson GT; Meibohm B; Lenaerts AJ; Ainsa J; Böttger EC; Lee RE
    ACS Infect Dis; 2017 Jan; 3(1):72-88. PubMed ID: 28081607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis.
    Wagh S; Rathi C; Lukka PB; Parmar K; Temrikar Z; Liu J; Scherman MS; Lee RE; Robertson GT; Lenaerts AJ; Meibohm B
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0174420. PubMed ID: 34424046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics.
    Bruhn DF; Scherman MS; Liu J; Scherbakov D; Meibohm B; Böttger EC; Lenaerts AJ; Lee RE
    Sci Rep; 2015 Sep; 5():13985. PubMed ID: 26365087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.
    Budha NR; Lee RB; Hurdle JG; Lee RE; Meibohm B
    Tuberculosis (Edinb); 2009 Sep; 89(5):378-85. PubMed ID: 19748318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis.
    Gonzalez-Juarrero M; Lukka PB; Wagh S; Walz A; Arab J; Pearce C; Ali Z; Ryman JT; Parmar K; Temrikar Z; Munoz-Gutierrez J; Robertson GT; Liu J; Lenaerts AJ; Daley C; Lee RE; Braunstein M; Hickey AJ; Meibohm B
    ACS Infect Dis; 2021 Oct; 7(10):2850-2863. PubMed ID: 34546724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux.
    Lee RE; Hurdle JG; Liu J; Bruhn DF; Matt T; Scherman MS; Vaddady PK; Zheng Z; Qi J; Akbergenov R; Das S; Madhura DB; Rathi C; Trivedi A; Villellas C; Lee RB; Rakesh ; Waidyarachchi SL; Sun D; McNeil MR; Ainsa JA; Boshoff HI; Gonzalez-Juarrero M; Meibohm B; Böttger EC; Lenaerts AJ
    Nat Med; 2014 Feb; 20(2):152-158. PubMed ID: 24464186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes.
    Temrikar ZH; Kodidela S; Kumar S; Liu J; Robertson GT; Lee RE; Hickey AJ; Gonzalez-Juarrero M; Meibohm B
    Tuberculosis (Edinb); 2023 May; 140():102342. PubMed ID: 37120915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sterilization of Mycobacterium tuberculosis infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies.
    Walz A; Lukka PB; Pearce C; Creissen E; Braunstein M; Hickey AJ; Meibohm B; Gonzalez-Juarrero M
    Tuberculosis (Edinb); 2019 Jul; 117():52-55. PubMed ID: 31378268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
    Robertson GT; Scherman MS; Bruhn DF; Liu J; Hastings C; McNeil MR; Butler MM; Bowlin TL; Lee RB; Lee RE; Lenaerts AJ
    J Antimicrob Chemother; 2017 Mar; 72(3):770-777. PubMed ID: 27999020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
    Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.
    Khan DD; Friberg LE; Nielsen EI
    J Antimicrob Chemother; 2016 Jul; 71(7):1881-4. PubMed ID: 26983860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.
    Vaddady PK; Lee RE; Meibohm B
    Future Med Chem; 2010 Aug; 2(8):1355-69. PubMed ID: 21359155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-Guéren.
    Ozeki Y; Igarashi M; Doe M; Tamaru A; Kinoshita N; Ogura Y; Iwamoto T; Sawa R; Umekita M; Enany S; Nishiuchi Y; Osada-Oka M; Hayashi T; Niki M; Tateishi Y; Hatano M; Matsumoto S
    PLoS One; 2015; 10(11):e0141658. PubMed ID: 26571296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naphthofuroquinone derivatives show strong antimycobacterial activities against drug-resistant Mycobacteria.
    Jang WS; Choi YS; Kim S; Jyoti MA; Seo H; Han J; Kim YS; Lyu J; Nam KW; Lee BE; Lee KI; Song HY
    J Chemother; 2017 Dec; 29(6):338-343. PubMed ID: 28281912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Vancomycin Susceptibility in Mycobacteria: a New Approach To Identify Synergistic Activity against Multidrug-Resistant Mycobacteria.
    Soetaert K; Rens C; Wang XM; De Bruyn J; Lanéelle MA; Laval F; Lemassu A; Daffé M; Bifani P; Fontaine V; Lefèvre P
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5057-60. PubMed ID: 26033733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents.
    Desai NC; Somani H; Trivedi A; Bhatt K; Nawale L; Khedkar VM; Jha PC; Sarkar D
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1776-83. PubMed ID: 26920799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.
    Bax HI; Bakker-Woudenberg IAJM; de Vogel CP; van der Meijden A; Verbon A; de Steenwinkel JEM
    Tuberculosis (Edinb); 2017 Jul; 105():80-85. PubMed ID: 28610791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB).
    Martins M; Viveiros M; Ramos J; Couto I; Molnar J; Boeree M; Amaral L
    Int J Antimicrob Agents; 2009 May; 33(5):479-82. PubMed ID: 19155160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phytogenic silver, gold, and bimetallic nanoparticles as novel antitubercular agents.
    Singh R; Nawale L; Arkile M; Wadhwani S; Shedbalkar U; Chopade S; Sarkar D; Chopade BA
    Int J Nanomedicine; 2016; 11():1889-97. PubMed ID: 27217751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.